Abstract
The somatostatin subtype 2A (sst2A) receptor, a member of the G protein-coupled receptor superfamily, mediates many of the neuroendocrine and neuromodulatory actions of somatostatin, and it represents the primary target for somatostatin analogs used in cancer therapy and tumor localization. Agonist stimulation leads to the rapid phosphorylation, endocytosis, and desensitization of the sst2A receptor; however, little is known about the role of phosphorylation in sst2A regulation. sst2A phosphorylation occurs on serine and threonine residues in the third intracellular loop and carboxyl terminus. Therefore, we generated mutant receptors in which serine (Ser-), threonine (Thr-), or both (Ser-/Thr-) residues in these regions were mutated to alanine. In contrast to the wild-type receptor, somatostatin treatment did not stimulate the phosphorylation of the Ser-/Thr- mutant, and it did not produce desensitization. Furthermore, internalization of the Ser-/Thr- mutant occurred 5 times more slowly than with the wild-type receptor. Mutating only the Ser residues did not inhibit either internalization or desensitization. In contrast, mutating only the Thr residues inhibited receptor endocytosis to the same extent as in the full mutant, but it did not affect receptor desensitization. In both the wild-type and Ser- receptors, agonist binding produced a stable arrestin-receptor complex that was maintained during receptor trafficking, whereas arrestin was not recruited to either the Thr- or the Ser-/Thr- receptors. These results demonstrate that agonist-stimulated receptor phosphorylation is necessary for both desensitization and rapid internalization of the sst2A receptor. However, sst2A receptor internalization and uncoupling can occur independently, involve different receptor phosphorylation sites, and exhibit different requirements for stable arrestin association.
Footnotes
-
This investigation was supported by research grants from the National Institute of Arthritis, Diabetes, Digestive, and Kidney Diseases (DK032234) and the Texas Advanced Technology Program (011618-0032-2001).
-
ABBREVIATIONS: GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase; sst2, somatostatin receptor subtype 2; CT, carboxyl terminus; IC3, third intracellular loop; PKC, protein kinase C; PPI, phosphatase inhibitors; SS14, the 14-amino acid form of somatostatin; HA, hemagglutinin; EGFP, enhanced green fluorescent protein; CHO, Chinese hamster ovary; PVDF, polyvinylidene difluoride; ELISA, enzyme-linked immunosorbent assay; PBS, phosphate-buffered saline; WT, wild type.
-
↵1 Current affiliation: PAREXEL International, Level 7, Northwick Park Hospital, Harrow, United Kingdom.
- Received May 29, 2007.
- Accepted November 2, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|